Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yhim, Ho-Young | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Kim, Jeong-A. | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Shim, Hyeok | - |
dc.contributor.author | Huh, Jooryung | - |
dc.contributor.author | Lee, Dae-Ho | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.date.accessioned | 2021-08-12T02:47:54Z | - |
dc.date.available | 2021-08-12T02:47:54Z | - |
dc.date.issued | 2012-07-01 | - |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.issn | 1097-0215 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/15004 | - |
dc.description.abstract | Primary breast diffuse large B-cell lymphoma (DLBCL) is an extremely rare presentation of non-Hodgkin's lymphoma that has been associated with poorer clinical outcomes compared with nodal DLBCL in the pre-rituximab era. The aim of this study was to investigate the impact of rituximab on clinical outcomes in patients with primary breast DLBCL. Data from 25 female patients with primary breast DLBCL receiving rituximab plus chemotherapy were matched to 75 female patients (1:3) with nodal DLBCL by following five established prognostic factors (age, Ann Arbor stage, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level and B symptoms). Overall survival (OS) was similar between primary breast and nodal DLBCL groups (3-year OS rate, 82.2% vs. 90.7%, respectively; p = 0.345). In the analysis of immunohistochemically defined prognostic subgroups, 19 of 20 available cases in the primary breast DLBCL group displayed a non-germinal center (GC) phenotype. Compared with patterns of recurrence, extranodal progression in the breast or central nervous system (CNS) was significantly higher in the primary breast DLBCL group than in the nodal DLBCL group (p < 0.001). Additionally, the stage-modified International Prognostic Index was the only independent prognostic factor for OS in this population. This suggests that clinical outcomes of primary breast DLBCL might no longer be inferior to those of nodal DLBCL in the rituximab era, which might be associated with the intrinsic biologic characteristics of the non-GC phenotype. However, despite including rituximab, extranodal progression in the breast or CNS was problematic. This study was registered at as no. NCT01266668. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1002/ijc.26352 | - |
dc.identifier.scopusid | 2-s2.0-84860223786 | - |
dc.identifier.wosid | 000303050100025 | - |
dc.identifier.bibliographicCitation | International Journal of Cancer, v.131, no.1, pp 235 - 243 | - |
dc.citation.title | International Journal of Cancer | - |
dc.citation.volume | 131 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 235 | - |
dc.citation.endPage | 243 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | NON-HODGKIN-LYMPHOMA | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | EXTRANODAL LYMPHOMA | - |
dc.subject.keywordPlus | BRITISH-COLUMBIA | - |
dc.subject.keywordPlus | CHOP | - |
dc.subject.keywordPlus | PHENOTYPE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | breast | - |
dc.subject.keywordAuthor | central nervous system | - |
dc.subject.keywordAuthor | diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | rituximab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.